DK0969877T3 - Fremgangsmåder til modulering af væksten af collaterale arterier og/eller andre arterier fra forudeksisterende arteriolære forbindelser - Google Patents

Fremgangsmåder til modulering af væksten af collaterale arterier og/eller andre arterier fra forudeksisterende arteriolære forbindelser

Info

Publication number
DK0969877T3
DK0969877T3 DK98924093T DK98924093T DK0969877T3 DK 0969877 T3 DK0969877 T3 DK 0969877T3 DK 98924093 T DK98924093 T DK 98924093T DK 98924093 T DK98924093 T DK 98924093T DK 0969877 T3 DK0969877 T3 DK 0969877T3
Authority
DK
Denmark
Prior art keywords
arteries
growth
collateral
arteriolar connections
methods
Prior art date
Application number
DK98924093T
Other languages
English (en)
Inventor
Wolfgang Schaper
Wulf D Ito
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of DK0969877T3 publication Critical patent/DK0969877T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/195Chemokines, e.g. RANTES
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Liquid Crystal Display Device Control (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK98924093T 1997-04-04 1998-04-01 Fremgangsmåder til modulering af væksten af collaterale arterier og/eller andre arterier fra forudeksisterende arteriolære forbindelser DK0969877T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97105647 1997-04-04
PCT/EP1998/001891 WO1998044953A1 (en) 1997-04-04 1998-04-01 Methods for the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections

Publications (1)

Publication Number Publication Date
DK0969877T3 true DK0969877T3 (da) 2003-03-24

Family

ID=8226664

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98924093T DK0969877T3 (da) 1997-04-04 1998-04-01 Fremgangsmåder til modulering af væksten af collaterale arterier og/eller andre arterier fra forudeksisterende arteriolære forbindelser

Country Status (10)

Country Link
US (2) US6592862B1 (da)
EP (2) EP1304123A3 (da)
JP (1) JP2001519795A (da)
AT (1) ATE232399T1 (da)
CA (1) CA2284922A1 (da)
DE (1) DE69811348T2 (da)
DK (1) DK0969877T3 (da)
ES (1) ES2187972T3 (da)
PT (1) PT969877E (da)
WO (1) WO1998044953A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528625B1 (en) * 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same
US7507705B2 (en) 1997-10-02 2009-03-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
US6749617B1 (en) 1997-11-04 2004-06-15 Scimed Life Systems, Inc. Catheter and implants for the delivery of therapeutic agents to tissues
US6727349B1 (en) 1998-07-23 2004-04-27 Millennium Pharmaceuticals, Inc. Recombinant anti-CCR2 antibodies and methods of use therefor
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
US6488930B1 (en) 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
US6245332B1 (en) 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
US6329510B1 (en) 1999-01-29 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-CCR1 antibodies and methods of use therefor
AU4544600A (en) * 1999-04-06 2000-10-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Pharmaceutical compositions comprising circulating blood cells, preferably monocytes and uses thereof
US20020034501A1 (en) * 2000-05-18 2002-03-21 Robert Pawliuk Methods and compositions for promoting angiogenesis using monocytes
AU2001261743C9 (en) * 2000-05-19 2006-07-06 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for reducing tumor growth and metastasis by inhibiting MCP-1 activity
EP1383551B1 (en) * 2000-11-08 2010-07-14 Boston Scientific Limited Multilumen catheter and implants for the delivery of therapeutic agents to tissues
US10590418B2 (en) 2001-07-23 2020-03-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for RNAi mediated inhibition of gene expression in mammals
DK2280070T3 (da) * 2001-07-23 2015-08-24 Univ Leland Stanford Junior Fremgangsmåde og sammensætninger til brug for RNAi-formidlet inhibering af genekspression i pattedyr
US20040151721A1 (en) 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179078A (en) * 1989-05-12 1993-01-12 Dana Farber Cancer Institute Method of suppressing tumor formation in vivo
DE69428460T2 (de) * 1994-05-16 2002-05-23 Human Genome Sciences, Inc. Chemotaktisches protein
EA001616B1 (ru) * 1995-02-28 2001-06-25 Зе Риджентс Оф Зи Юнивесити Оф Кэлифоньэ Способ лечения болезни сердца, способ лечения недостаточности периферических сосудов и способ ограничения доставки и экспрессии трансгенной конструкции в определенном органе или структуре
US6544543B1 (en) * 2000-12-27 2003-04-08 Advanced Cardiovascular Systems, Inc. Periodic constriction of vessels to treat ischemic tissue

Also Published As

Publication number Publication date
DE69811348D1 (de) 2003-03-20
JP2001519795A (ja) 2001-10-23
ATE232399T1 (de) 2003-02-15
EP1304123A3 (en) 2003-11-19
EP0969877A1 (en) 2000-01-12
DE69811348T2 (de) 2003-12-24
WO1998044953A1 (en) 1998-10-15
PT969877E (pt) 2003-06-30
EP1304123A2 (en) 2003-04-23
US20040023881A1 (en) 2004-02-05
US6592862B1 (en) 2003-07-15
ES2187972T3 (es) 2003-06-16
CA2284922A1 (en) 1998-10-15
EP0969877B1 (en) 2003-02-12

Similar Documents

Publication Publication Date Title
DK1019082T3 (da) Fremgangsmåde til moduleringen af neovaskularisering og/eller væksten af kollaterale arterier og/eller andre arterier fra forudeksisterende arteriolære forbindelser
DK0969877T3 (da) Fremgangsmåder til modulering af væksten af collaterale arterier og/eller andre arterier fra forudeksisterende arteriolære forbindelser
DE60144145D1 (de) Subtilisin-variante
DK161015C (da) Blanding til anvendelse ved ekstern paavisning og lokalisering af en blodprop
DE69733247D1 (de) Humanisiertes grünes-fluoreszenzprotein und methoden
CY1115634T1 (el) Μεσα ανταγωνιστικης επιλεκτικης συνδεσης της πρωτεϊνης συνδεσης οστεοπροτεγερινης
BR9812096A (pt) Proteìna receptora/ligante solúvel interleucina-6 quimérica, seus análogos e seus usos
CY1105364T1 (el) Μεθοδοι και συνθεσεις διαμορφωσης ανοσοποιησης
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
ATE342359T1 (de) Design von beta-faltblatt-proteinen mit spezifischen bindungseigenschaften
DK0643726T3 (da) Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei
DK0961780T3 (da) Proteinmarkörer for lungecancer og anvendelse deraf
ATE490262T1 (de) Abschwächung der immunogenizität von fusionsproteinen
ES2185705T3 (es) Proteina bifuncional, preparacion y uso.
BR9811039A (pt) Citocina de mamìferos: interleucina-b30 e reagentes relacionados
ATE339507T1 (de) Erythropoietin-analog-menschliches serum-albumin fusionsprotein
DE69111440D1 (de) Methoden und zusammensetzungen zur impfung gegen hiv.
DK0479948T3 (da) Sammensætninger og fremgangsmåder til syntese af natriuretisk protein-receptor B og anvendelsesfremgangsmåder
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
DE69821376D1 (de) Verfahren zur proteinrückfaltung durch verwendung zwitterionischer wirkstoffe von niedrigem molekulargewicht
ATE384263T1 (de) Verfahren zur bestimmung von biologischen agenzien in lebenden zielzellen
DE69714775D1 (de) Verfahren zur Tötung von Zielzellen in geernteten Zellpopulationen mit Hilfe von zwei Immunotoxinen
AR022237A1 (es) Citoquinas mamiferas purificadas; reactivos y metodos relacionados
DE60034966D1 (de) Auswertung von biologischen mitteln in lebenden zielzellen